Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis
Introduction Patients with multiple myeloma (MM) face heightened infection susceptibility,
particularly severe risks from COVID-19. This study, the first systematic review in its domain …
particularly severe risks from COVID-19. This study, the first systematic review in its domain …
Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab
D Jin, J He, W Wu, X Han, J Le, W Shu, J Fu… - Cancer …, 2024 - Wiley Online Library
Despite concerns about an increased risk of adverse outcomes following coronavirus
disease (COVID‐19) in multiple myeloma patients treated with anti‐CD38 Abs, the impact of …
disease (COVID‐19) in multiple myeloma patients treated with anti‐CD38 Abs, the impact of …
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Patients with hematologic malignancies (HMs) are at a significantly higher risk of contracting
COVID-19 and experiencing severe outcomes compared to individuals without HMs. This …
COVID-19 and experiencing severe outcomes compared to individuals without HMs. This …
Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies
TY Wu, WT Tsai, KH Chen, ST Huang… - Journal of Microbiology …, 2024 - Elsevier
Background Patients with hematological malignancies (HM) were at a high risk of
developing severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess …
developing severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess …